Live vaccines—a short‐cut to cancer viro‐immunotherapy

Tumour immunotherapies have been a breakthrough in clinical oncology but only a few patients benefit from this progress. Additional interventions that sensitize immunologically cold tumours for the administration of checkpoint modifiers are urgently needed. In this issue of EMBO Molecular Medicine , Aznar et al present the already approved yellow fever vaccine 17D as an oncolytic agent for tumour immunoactivation. In tumour‐bearing mice, they demonstrated a convincing synergy of the vaccine with CD 137 agonistic antibodies resulting in significantly improved survival.